Phase II randomized study of weekly docetaxel alone or plus UFUR treatment in non-small cell lung cancer patients who failed previous chemotherapy

Kun Ta Chou, Yuh Min Chen, Jen Fu Shih, Reury Perng Perng, Chun Ming Tsai, Jacqueline Whang-Peng

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose: This study aimed to assess the feasibility and efficacy of adding UFUR (UFT, tegafur/uracil) into weekly docetaxel treatment for non-small cell lung cancer (NSCLC) patients who failed previous platinum-based chemotherapy. Methods: Patients were randomized into two arms: docetaxel 40 mg/m2 intravenous infusion (IV) on days 1 and 8 of every 3 weeks (arm D), and docetaxel 35 mg/m2 IV on days 1 and 8 plus daily oral UFUR 150 mg/m2 of every 3 weeks (arm DU), with arm D as a control arm. Treatment was given to a maximum of 6 cycles and carried out in the outpatient clinic. Results: From January 2005 to March 2006, 48 patients were enrolled and randomized into the study, with 24 patients in each arm. The mean number of cycles of treatment was 4 in the D arm and 3.5 in the DU arm. Objective response rates were 29.2% in the D arm and 8.3% in the DU arm (p = 0.067). Toxicities were few and mild in degree in both arms. Median time to disease progression was 4.5 months in the D arm and 2.1 months in the DU arm (p = 0.4682). Median survival time was 10.9 months in the D arm and 15.2 months in the DU arm (p = 0.8442). Conclusions: The addition of UFUR to weekly docetaxel treatment did not improve response rate and time to disease progression in NSCLC patients who failed previous platinum-based chemotherapy.

Original languageEnglish
Pages (from-to)64-68
Number of pages5
JournalLung Cancer
Volume59
Issue number1
DOIs
Publication statusPublished - Jan 2008
Externally publishedYes

Fingerprint

docetaxel
Tegafur
Uracil
Non-Small Cell Lung Carcinoma
Drug Therapy
Platinum
Intravenous Infusions
Disease Progression
Therapeutics
Ambulatory Care Facilities
Survival

Keywords

  • Docetaxel
  • Non-small cell lung cancer
  • Salvage therapy
  • UFUR

ASJC Scopus subject areas

  • Oncology

Cite this

Phase II randomized study of weekly docetaxel alone or plus UFUR treatment in non-small cell lung cancer patients who failed previous chemotherapy. / Chou, Kun Ta; Chen, Yuh Min; Shih, Jen Fu; Perng, Reury Perng; Tsai, Chun Ming; Whang-Peng, Jacqueline.

In: Lung Cancer, Vol. 59, No. 1, 01.2008, p. 64-68.

Research output: Contribution to journalArticle

Chou, Kun Ta ; Chen, Yuh Min ; Shih, Jen Fu ; Perng, Reury Perng ; Tsai, Chun Ming ; Whang-Peng, Jacqueline. / Phase II randomized study of weekly docetaxel alone or plus UFUR treatment in non-small cell lung cancer patients who failed previous chemotherapy. In: Lung Cancer. 2008 ; Vol. 59, No. 1. pp. 64-68.
@article{87f6a54612a84c738944fe88f2907636,
title = "Phase II randomized study of weekly docetaxel alone or plus UFUR treatment in non-small cell lung cancer patients who failed previous chemotherapy",
abstract = "Purpose: This study aimed to assess the feasibility and efficacy of adding UFUR (UFT, tegafur/uracil) into weekly docetaxel treatment for non-small cell lung cancer (NSCLC) patients who failed previous platinum-based chemotherapy. Methods: Patients were randomized into two arms: docetaxel 40 mg/m2 intravenous infusion (IV) on days 1 and 8 of every 3 weeks (arm D), and docetaxel 35 mg/m2 IV on days 1 and 8 plus daily oral UFUR 150 mg/m2 of every 3 weeks (arm DU), with arm D as a control arm. Treatment was given to a maximum of 6 cycles and carried out in the outpatient clinic. Results: From January 2005 to March 2006, 48 patients were enrolled and randomized into the study, with 24 patients in each arm. The mean number of cycles of treatment was 4 in the D arm and 3.5 in the DU arm. Objective response rates were 29.2{\%} in the D arm and 8.3{\%} in the DU arm (p = 0.067). Toxicities were few and mild in degree in both arms. Median time to disease progression was 4.5 months in the D arm and 2.1 months in the DU arm (p = 0.4682). Median survival time was 10.9 months in the D arm and 15.2 months in the DU arm (p = 0.8442). Conclusions: The addition of UFUR to weekly docetaxel treatment did not improve response rate and time to disease progression in NSCLC patients who failed previous platinum-based chemotherapy.",
keywords = "Docetaxel, Non-small cell lung cancer, Salvage therapy, UFUR",
author = "Chou, {Kun Ta} and Chen, {Yuh Min} and Shih, {Jen Fu} and Perng, {Reury Perng} and Tsai, {Chun Ming} and Jacqueline Whang-Peng",
year = "2008",
month = "1",
doi = "10.1016/j.lungcan.2007.07.016",
language = "English",
volume = "59",
pages = "64--68",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Phase II randomized study of weekly docetaxel alone or plus UFUR treatment in non-small cell lung cancer patients who failed previous chemotherapy

AU - Chou, Kun Ta

AU - Chen, Yuh Min

AU - Shih, Jen Fu

AU - Perng, Reury Perng

AU - Tsai, Chun Ming

AU - Whang-Peng, Jacqueline

PY - 2008/1

Y1 - 2008/1

N2 - Purpose: This study aimed to assess the feasibility and efficacy of adding UFUR (UFT, tegafur/uracil) into weekly docetaxel treatment for non-small cell lung cancer (NSCLC) patients who failed previous platinum-based chemotherapy. Methods: Patients were randomized into two arms: docetaxel 40 mg/m2 intravenous infusion (IV) on days 1 and 8 of every 3 weeks (arm D), and docetaxel 35 mg/m2 IV on days 1 and 8 plus daily oral UFUR 150 mg/m2 of every 3 weeks (arm DU), with arm D as a control arm. Treatment was given to a maximum of 6 cycles and carried out in the outpatient clinic. Results: From January 2005 to March 2006, 48 patients were enrolled and randomized into the study, with 24 patients in each arm. The mean number of cycles of treatment was 4 in the D arm and 3.5 in the DU arm. Objective response rates were 29.2% in the D arm and 8.3% in the DU arm (p = 0.067). Toxicities were few and mild in degree in both arms. Median time to disease progression was 4.5 months in the D arm and 2.1 months in the DU arm (p = 0.4682). Median survival time was 10.9 months in the D arm and 15.2 months in the DU arm (p = 0.8442). Conclusions: The addition of UFUR to weekly docetaxel treatment did not improve response rate and time to disease progression in NSCLC patients who failed previous platinum-based chemotherapy.

AB - Purpose: This study aimed to assess the feasibility and efficacy of adding UFUR (UFT, tegafur/uracil) into weekly docetaxel treatment for non-small cell lung cancer (NSCLC) patients who failed previous platinum-based chemotherapy. Methods: Patients were randomized into two arms: docetaxel 40 mg/m2 intravenous infusion (IV) on days 1 and 8 of every 3 weeks (arm D), and docetaxel 35 mg/m2 IV on days 1 and 8 plus daily oral UFUR 150 mg/m2 of every 3 weeks (arm DU), with arm D as a control arm. Treatment was given to a maximum of 6 cycles and carried out in the outpatient clinic. Results: From January 2005 to March 2006, 48 patients were enrolled and randomized into the study, with 24 patients in each arm. The mean number of cycles of treatment was 4 in the D arm and 3.5 in the DU arm. Objective response rates were 29.2% in the D arm and 8.3% in the DU arm (p = 0.067). Toxicities were few and mild in degree in both arms. Median time to disease progression was 4.5 months in the D arm and 2.1 months in the DU arm (p = 0.4682). Median survival time was 10.9 months in the D arm and 15.2 months in the DU arm (p = 0.8442). Conclusions: The addition of UFUR to weekly docetaxel treatment did not improve response rate and time to disease progression in NSCLC patients who failed previous platinum-based chemotherapy.

KW - Docetaxel

KW - Non-small cell lung cancer

KW - Salvage therapy

KW - UFUR

UR - http://www.scopus.com/inward/record.url?scp=37549016343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37549016343&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2007.07.016

DO - 10.1016/j.lungcan.2007.07.016

M3 - Article

VL - 59

SP - 64

EP - 68

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 1

ER -